Invasive Pneumococcal Disease During the COVID-19 Pandemic in Calgary, Canada

Simple item page
dc.contributor.authorRicketson, Leah
dc.contributor.authorKellner, James
dc.contributor.authorCASPER Investigators
dc.date.accessioned2022-06-15T21:09:31Z
dc.date.available2022-06-15T21:09:31Z
dc.date.issued2022-06-20
dc.description12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12), Toronto, Canada, June 19-23, 2022en_US
dc.description.abstractSimilar to other regions and countries, there was a dramatic decline in the incidence of IPD and other contagious infectious diseases in Calgary after the start of the COVID-19 pandemic. The initial decline in overall IPD incidence (IRR 0.22 in 2nd quarter of 2020 vs average for 2011-19) was particularly dramatic and was sustained until mid-2021 in adults and the end of 2021 in children. Presumably, the reduction was related to society-side measures implemented to reduce transmission of the SARS-CoV-2 virus, with such measures also reducing the transmission of other contagious diseases including pneumococcus and influenza. These measures were highest in 2020 and gradually reduced through 2021. In addition, IPD uncommonly occurs as a complication of SARS-CoV-2 infections, unlike other viruses such as influenza and RSV, where secondary pneumococcal infections occur readily. The higher rebound in PCV13 serotype IPD in adults in 2021 (compared with non-PCV13 serotype IPD) of interest. Childhood PCV programs have demonstrated a strong herd-protection effect to prevent vaccine-serotype IPD in adults. There was a significant decline in routine childhood vaccination rates in Alberta in 2020 (https://bmjopen.bmj.com/content/12/1/e055968). There may be an association between such declines and a reduction in the level of herd protection that influences vaccine-serotype IPD in adults.en_US
dc.identifier.citationRicketson, L., Kellner, J. D., & CASPER Investigators (2022, June 19-23). Invasive Pneumococcal Disease During the COVID-19 Pandemic in Calgary, Canada. [Poster presentation]. 12th International Symposium on Pneumococci and Pneumococcal Diseases, Toronto, Canada. https://isppd.kenes.comen_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/39829
dc.identifier.urihttp://hdl.handle.net/1880/114741
dc.language.isoengen_US
dc.publisher.departmentCommunity Health Sciencesen_US
dc.publisher.departmentMicrobiology, Immunology & Infectious Diseasesen_US
dc.publisher.departmentPaediatricsen_US
dc.publisher.facultyCumming School of Medicineen_US
dc.publisher.institutionUniversity of Calgaryen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectpneumococcusen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectinvasive pneumococcal diseaseen_US
dc.titleInvasive Pneumococcal Disease During the COVID-19 Pandemic in Calgary, Canadaen_US
dc.typeconference posteren_US
ucalgary.item.requestcopytrueen_US
ucalgary.scholar.levelFacultyen_US
ucalgary.scholar.levelOtheren_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kellner ISPPD 2022 388 IPD COVID-19 FINAL.pdf
Size:
747.34 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.92 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cumming School of Medicine Research & Publications